Analysts Set SI-BONE, Inc. (NASDAQ:SIBN) Price Target at $23.00

Shares of SI-BONE, Inc. (NASDAQ:SIBN) have earned a consensus recommendation of “Buy” from the six research firms that are presently covering the company, Marketbeat reports. Six research analysts have rated the stock with a buy recommendation. The average 1-year target price among analysts that have issued a report on the stock in the last year is $23.00.

Several equities research analysts recently weighed in on the company. Truist Financial raised their price objective on SI-BONE from $16.00 to $18.00 and gave the company a “buy” rating in a report on Wednesday, November 13th. Needham & Company LLC restated a “buy” rating and set a $19.00 price target on shares of SI-BONE in a report on Monday, January 13th.

Insider Transactions at SI-BONE

In other news, CEO Laura Francis sold 10,048 shares of the business’s stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $12.58, for a total transaction of $126,403.84. Following the completion of the sale, the chief executive officer now owns 482,875 shares in the company, valued at $6,074,567.50. The trade was a 2.04 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Anshul Maheshwari sold 2,439 shares of the firm’s stock in a transaction on Monday, November 18th. The shares were sold at an average price of $12.68, for a total transaction of $30,926.52. Following the completion of the transaction, the chief financial officer now directly owns 194,623 shares in the company, valued at $2,467,819.64. This trade represents a 1.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 27,344 shares of company stock worth $357,292. Company insiders own 3.90% of the company’s stock.

Institutional Trading of SI-BONE

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. FMR LLC boosted its holdings in SI-BONE by 103.6% during the 3rd quarter. FMR LLC now owns 2,354 shares of the company’s stock worth $33,000 after acquiring an additional 1,198 shares during the last quarter. Mainstream Capital Management LLC bought a new stake in SI-BONE during the 4th quarter valued at $53,000. R Squared Ltd purchased a new stake in SI-BONE during the 4th quarter worth about $73,000. Walleye Capital LLC bought a new position in shares of SI-BONE in the third quarter valued at approximately $144,000. Finally, Proficio Capital Partners LLC bought a new stake in SI-BONE during the 4th quarter worth approximately $155,000. 98.11% of the stock is owned by institutional investors.

SI-BONE Price Performance

SIBN stock opened at $17.07 on Thursday. SI-BONE has a 1 year low of $11.70 and a 1 year high of $21.64. The company has a debt-to-equity ratio of 0.22, a current ratio of 8.25 and a quick ratio of 7.22. The stock has a market cap of $715.88 million, a price-to-earnings ratio of -18.55 and a beta of 1.17. The company has a 50 day simple moving average of $15.03 and a 200 day simple moving average of $14.52.

About SI-BONE

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.